Warfarin in non-valvular atrial fibrillation by Dalby, Anthony J et al.
FORUM
901  December 2013, Vol. 103, No. 12  SAMJ
Although the benefits of the novel oral anticoagulants 
(dabigatran, rivaroxaban, and apixaban) may surpass 
warfarin in non-valvular atrial fibrillation (AF), their 
high cost makes them unaffordable to most South 
Africans. Therefore, it remains imperative that optimal 
management of warfarin anticoagulation is provided to these patients. 
Warfarin’s superiority over antiplatelet therapies in preventing stroke 
and systemic embolism in patients with non-valvular AF has been 
firmly established for more than a decade. Warfarin reduces stroke risk 
by 68%.[1] Optimal results depend on maintenance of the international 
normalised ratio (INR) within the therapeutic range (INR 2 - 3). Lower 
values are associated with an excess of thrombo-embolic events and 
higher values with increased bleeding.[2,3] Notably, in clinical trials and 
in practice the ideal therapeutic effect is obtained in less than half of all 
patients, in the remainder, almost 40% are in a sub-therapeutic range 
while approximately 20% are supratherapeutic.[4,5]
Anticoagulation for non-valvular AF balances the risk of thrombo-
embolism against the risk of haemorrhage. The CHA2DS2-VASc score[6] 
most accurately predicts the risk of thrombo-embolism and stroke 
(Table 1). Anticoagulation is recommended for a CHA2DS2-VASc score 
of >1; essentially this includes all non-valvular AF patients with the 
exception of those <65 years of age with lone AF. The risk of bleeding 
is predicted from the HAS-BLED score (Table 2)[7] which should not be 
used to deny anticoagulation to anyone, other than those at low risk of 
thrombo-embolism.[6]
Problems of warfarin use
Warfarin has a narrow therapeutic window, slow onset and 
offset of action, and an unpredictable response demanding a 
frequent monitoring of the INR, dose adjustment and awareness of 
interactions with food and with other drugs. These issues require 
careful explanation to patients to ensure their compliance. The 
clinician must manage the logistics of patient education, ongoing 
support and regular drug administration. Physicians’ resistance to 
using warfarin effectively has been ascribed to the fear of causing 
intracranial haemorrhage.[8] However, in a large cohort study 
the risk of intracranial bleeding on warfarin exceeded the risk 
of ischaemic stroke off warfarin in only 0.4% of patients. Thus, 
almost all patients with AF have more to gain than to lose from 
anticoagulation with warfarin.[9] 
Initiating warfarin therapy
A baseline prothrombin time should be obtained in all patients. A 
personal or family history of bleeding merits investigation before 
starting treatment. Warfarin therapy should be commenced without a 
loading dose, usually at 5 mg daily. A lower starting dose is appropriate 
in the aged, the frail or malnourished, and those with a low body 
weight, congestive heart failure or impaired kidney function or with 
concomitant medication increasing warfarin sensitivity.[10] The starting 
dose may be estimated using an algorithm based upon the clinical and 
demographic patient characteristics including genetic information if 
available (http://www.warfarindosing.org/Source/Home.aspx). 
It takes several days to fully establish warfarin’s anticoagulant effect. 
When anticoagulation is required immediately, full anticoagulant 
doses of unfractionated heparin (UH) or low molecular weight 
heparin (LMWH) should be given concomitantly until 4 days after a 
therapeutic INR is reached. Two consecutive INR values should be in 
the therapeutic range during the overlap.
Once the therapeutic range (INR 2 - 3) is reached, INR testing 
should be repeated at least twice at 2 - 4-day intervals to ensure the 
stability of anticoagulation. 
Maintenance of a therapeutic INR
Arbitrary warfarin dose adjustment frequently overcorrects the INR. Not 
adjusting the dose when the INR is in range and only making small (10 
- 15%) adjustments for the vast majority of those out of range improves 
the time in therapeutic range and clinical outcomes.[11] Changes in dose 
are best guided by an algorithm promoting minor changes in the total 
weekly warfarin dose and reassessing the effect of the change within a 
week (Table 3). 
Minor bleeding is a common occurrence in anticoagulated patients 
and should not readily lead to dose adjustment or discontinuation of 
therapy.[12]
When the INR deviates above 5 in patients who are not bleeding, 
1 - 2 doses of warfarin should be withheld and the maintenance 
dose adjusted downwards. Should the INR rise above 8, 1 - 5 mg of 
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vitamin K should be given orally and the INR checked 24 h later to 
assess whether further vitamin K is needed.[13]
INR testing should occur at least monthly after a stable warfarin 
dose is achieved.
Self-monitoring and self-management of oral anticoagulation 
is safe for suitable patients of all ages and reduces thrombo-
embolic events by almost 50%.[14] In South Africa, the cost of home 
monitoring is similar to the cost of INR testing and dosing by 
pathology laboratories.
Temporary withdrawal of warfarin in 
the peri-operative period
Prolonged withdrawal of warfarin before major surgery is associated 
with a high risk of systemic embolism if alternative anticoagulation is 
not provided. However, if the INR is in the therapeutic range warfarin 
need not be withdrawn for minor surgical procedures (Table 4), or 
pacemaker or cardiac defibrillator implantation.[15,16] 
Bridging is required for major surgery, which means the timeous 
preoperative withdrawal of warfarin while introducing UH or LMWH 
prior to surgery, and the postoperative reintroduction of anticoagulation. 
Based upon the prevailing INR, warfarin should be withdrawn in 
sufficient time to allow the INR to fall. The patient’s usual warfarin 
dose should be taken into account; the lower the usual dose, the 
longer it may take. Of patients whose INR is in the therapeutic 
range, 93% will typically have an INR of <1.5 five days after 
stopping warfarin. [17] The hiatus in anticoagulation may be bridged 
with either UH or LMWH. Out-of-hospital self-administration 
of 1  mg/ kg enoxaparin 12-hourly subcutaneously is more cost-
effective (instruction on injection technique should be provided). 
LMWH is usually introduced 36 h after stopping warfarin. The dose 
of enoxaparin should be reduced by 25% in the elderly and those 
weighing <60  kg. In severe kidney dysfunction the dose frequency 
should be reduced to 1  mg/kg daily to compensate for diminished 
renal excretion. Dose adjustment according to anti-factor Xa (anti-
FXa) activity measured 2 - 3  h after administration is suggested 
in patients receiving decreased doses, those with decreased renal 
function and obese patients (who may need larger doses).[18] An anti-
FXa therapeutic target value of 0.5 - 1 IU/ml is suggested although it 
has not been validated.[19] UH or LMWH should be withdrawn during 
the last 24 h before surgery. 
In patients at high risk of intraoperative bleeding it is safe to 
operate when the INR is <1.5.[20]
Bridging for elective surgery
The decision to bridge balances thrombo-embolic risk against the 
risk of peri-operative haemorrhage.[21] The input and concurrence 
of the surgeon is invaluable. Although the incidence of thrombo-
embolism may be similar with bridging or no bridging, bridging 
may be associated with a higher risk of bleeding.[22] However, 
generalisation is difficult because the timing of warfarin withdrawal, 
the type, dose and timing of heparin used to replace warfarin, and the 
reintroduction of anticoagulation postoperatively varied significantly 
among studies. 
Patients at high and moderate thrombo-embolic risk (CHA2DS2-
VASc score >4) should receive the shorter-acting anticoagulant in 
full dose, whereas in those at lower risk a low-dose regimen or no 
bridging may be sufficient.[23]
Anticoagulation is reintroduced as soon as feasible after surgery, 
using either UH or LMWH in combination with warfarin. The 
UH/LMWH dose used depends upon the residual bleeding risk as 
determined by the surgeon. It is prudent to begin with lower doses 
and up-titrate daily according to the observed response. Warfarin 
is usually recommenced at the dose used preoperatively but may 
require adjustment if medications interacting with warfarin have 
been introduced peri-operatively. The INR should be measured daily 
during this phase. UH/LMWH should be continued until 4 days after 
a therapeutic INR is reached. Two consecutive INR values should be 
in the therapeutic range during the overlap.
Table 5 outlines a protocol used for bridging therapy.[15]
Table 1. The CHA2DS2-VASc score: A point-based, risk-factor 
approach to the assessment of stroke risk[6]
Letter Risk factor Score
C Congestive heart failure/LV dysfunction 1
H Hypertension 1
A2 Age ≥75 years 2
D Diabetes mellitus 1
S2 Stroke/TIA/thrombo-embolism 2
V Vascular disease 1
A Age 65 - 74 years 1
Sc Sex category (i.e. female) 1
Max. score 9
LV = left ventricular; TIA = transient ischaemic attack.
Table 2. The HAS-BLED score: The clinical characteristics 
contributing to the risk of bleeding[6]
Letter Clinical characteristic Score
H Hypertension 1
A Abnormal renal and/or liver function 1 or 2*
S Stroke 1
B Bleeding 1
L Labile INRs 1
E Elderly (age >65 years) 1
D Drugs and/or alcohol 1 or 2*
Max. score 9
INRs = international normalised ratios.
*1 point each.
Table 3. Algorithm for maintenance dosing of warfarin* 
INR† Dose adjustment‡ Retest
<1.5 Increase by 15% 1 week
>1.5 - <2 Increase by 10% 1 week
2 - 3 No change 
3 - <4 Decrease by 10% 1 week
4 - <5 Hold dose for one day, then 
decrease by 10% 
3 - 7 days
5 - <8 Hold dose until INR is therapeutic, then 
decrease by 15%
2 days
INR = international normalised ratio.
*Adapted from van Spall et al.[11]
† If the INR is >5 and there is a high risk of bleeding, or if the INR is >8, administer 1 - 5 mg 
vitamin K orally. Patients with an INR >8 should be assessed clinically for the presence of 
bleeding.
‡Calculated on the total weekly dose.
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Withdrawal for urgent and 
emergent surgery
Although there are no specific antidotes for warfarin, rapid and 
effective reversal of its effect is possible, in contrast to the novel 
oral anticoagulants for which specific reversing agents are presently 
lacking. [23] When urgent surgical intervention is indicated, the INR 
should be measured immediately. As vitamin K is slow-acting, it will 
most frequently be necessary to administer both prothrombin complex 
concentrate (PCC) and vitamin K intravenously to correct the INR to 
an acceptable level in patients requiring surgery within 12 h. If surgery 
can be delayed for >12 h, vitamin K alone may suffice.[13] In either case 
the INR should be monitored frequently as it may rise again once the 
effects of the reversing agents dissipate. 
Warfarin interactions 
There are significant risks of drug-drug, drug-food and drug-herb 
interactions with warfarin. Courses of antibiotics or non-steroidal 
anti-inflammatories most frequently perturb warfarin’s effect. 
Although a large number of interactions have been described, most 
report on potentiation of warfarin’s effect in a single case.[24] The INR 
should be monitored frequently when any new drug is introduced in 
a patient taking warfarin.
Management of bleeding with warfarin
Anticoagulant-associated bleeding is serious. In patients admitted for 
vitamin K antagonist-associated bleeding, the in-hospital mortality 
rate was 7.6% and 90-day mortality was 14%; 15% of survivors were 
dependent on help with activities of daily living thereafter.[25] The INR 
should be checked immediately whenever bleeding occurs. If the INR 
is within the therapeutic range, warfarin should be continued and 
the source of bleeding treated on its own merits. Significant bleeding 
should be treated with 1 - 3 mg vitamin K given by an intravenous or 
oral route. In major bleeding, warfarin can be reversed rapidly by 25 
- 50 U/kg four-factor PCC and 5 mg vitamin K given intravenously. 
Fresh frozen plasma produces suboptimal reversal and should be 
used only when PCC is unavailable. Recombinant factor VIIa is not 
recommended for emergency reversal.[13]
Table 4. Procedures that can be performed without 
discontinuing warfarin[15]
Ophthalmological Cataract surgery
Trabeculectomy
Dental Uncomplicated extraction
Dental hygiene
Restorations 
Endodontics
Prosthetics
Periodontal therapy
Dermatological Chemosurgery for skin cancer (Mohs surgery)
Simple excisions
Gastrointestinal Diagnostic OGD
Colonoscopy without biopsy
Diagnostic ERCP
Biliary stent without sphincterotomy
EUS without biopsy
Push enteroscopy
OGD = oesophagogastroduodenoscopy; ERCP = endoscopic retrograde cholangio-
pancreatography; EUS = endoscopic ultrasonography.
Table 5. Protocol for bridging therapy for elective surgery when the temporary withdrawal of warfarin is required* 
Day Protocol
Before surgery
-7 Check INR
-6 Stop warfarin if INR is 3 - 4.5 or if regular warfarin dose unusually low
-5 Stop warfarin if INR is 2 - 3 or if regular warfarin dose unusually high
-4 Start short-acting anticoagulant (UH/LMWH)
Enoxaparin preferred: 1 mg/kg 12-hourly. Adjust dose in the elderly, low body weight, frail, impaired kidney function 
Measure anti-FXa 2 - 3 h after administration, especially when dose adjustment is required 
-1 Stop short-acting anticoagulant 24 h before surgery
Check INR
If INR <1.5 (some surgeons prefer <1.2) proceed to surgery
Day of surgery
0 No anticoagulant
Use mechanical prophylaxis to prevent DVT 
After surgery
+1 Minor surgery: Commence full-dose LMWH
Major surgery: Commence reduced-dose LMWH 
Recommence warfarin in usual dose. Adjust dose if medication has been introduced that could influence warfarin’s effect 
Order daily INR
+2 and beyond Consider up-titration of LMWH if not on already on full dose
Continue warfarin and LMWH until INR >2 for 4 consecutive days
INR = international normalised ratio; UH = unfractionated heparin; LMWH = low molecular weight heparin; anti-FXa = anti-factor Xa; DVT = deep venous thrombosis.
*Adapted from Jaffer.[15]
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Warfarin in chronic kidney disease
Chronic kidney disease (CKD) increases the risk of both stroke 
and bleeding in non-valvular AF.[26] Because INR in CKD patients is 
often labile, such patients require lower doses of warfarin and more 
frequent testing and dose adjustment.[27] While warfarin effectively 
reduces stroke risk and is safe in moderate stage 3 CKD (creatinine 
clearance 30 - 60 ml/min), its value is less certain in end-stage renal 
disease.[28,29]
Discontinuing warfarin when 
commencing treatment with a novel 
oral anticoagulant
When changing to one of the novel oral anticoagulants, warfarin 
should be withdrawn and the INR monitored daily. The novel oral 
anticoagulant may be commenced once the INR has fallen below 
2. However, a survey of dabigatran reported increased rates of both 
thrombo-embolism and bleeding among previous warfarin users 
during the early months of the transition.[30]
Discontinuing a novel oral 
anticoagulant when commencing 
warfarin treatment
As highlighted by the experience with rivaroxaban, the withdrawal of 
the novel oral anticoagulants may lead to inadequate anticoagulation 
and thrombo-embolism.[31] As all the novel oral anticoagulants have a 
short duration of action, warfarin should be commenced on the day 
after withdrawal in combination with bridging therapy if the risk of 
thrombo-embolism is high. The INR should be monitored frequently 
until the therapeutic range is achieved. 
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